Thank you for that article. There are some who just don't get that GETA's Tesetaxel, if approved, will "fill an unmet medical need."
"Many investors don’t understand the importance of a Fast Track designation, and its purpose in aligning the drug towards commercial success. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need."
"...general Gastric cancer drug market...is projected to double to nearly $1.5 billion in 2018. According to a recent report published on News-Medical.net, ” Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and health care issues, finds that the gastric cancer drug market — driven by the launch of several targeted agents over the next few years — will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.”
Yup, enough said!
;)
News 
Market Data 
Discover 
